Co-Authors
This is a "connection" page, showing publications co-authored by Jason Glanz and Ousseny Zerbo.
Connection Strength
1.386
-
Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non-Vaccine-Targeted Infections From 24 Through 47 Months of Age. JAMA. 2018 03 06; 319(9):906-913.
Score: 0.640
-
Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. Ann Intern Med. 2024 Jan 09.
Score: 0.240
-
Order of Live and Inactivated Vaccines and Risk of Non-vaccine-targeted Infections in US Children 11-23 Months of Age. Pediatr Infect Dis J. 2020 03; 39(3):247-253.
Score: 0.184
-
Impact of the COVID-19 Pandemic on Health Care Utilization in the Vaccine Safety Datalink: Retrospective Cohort Study. JMIR Public Health Surveill. 2024 Jan 23; 10:e48159.
Score: 0.060
-
Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022 08 19; 40(35):5153-5159.
Score: 0.054
-
Safety of COVID-19 Vaccination in US Children Ages 5-11 Years. Pediatrics. 2022 May 18.
Score: 0.054
-
Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic. Vaccine. 2022 05 20; 40(23):3150-3158.
Score: 0.053
-
Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021 Sep 03.
Score: 0.051
-
COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
Score: 0.050